KZA Media Thread, page-1893

Kazia Therapeutics NASDAQ Updated Mar 26, 2022 - Stock twits

LabMan 10:19 AM
$KZIA The catalytic domains of the p110 subunits and mTOR are structurally similar, however the latter has distinct growth factor regulators within the phosphatidylinositol pathway. For the first time, we hear from John Hopkins at AACR 8th April, of the ability of the drug" to fully inhibit the activation of both complexes"
QUOTE {Previously, we have identified high activation of both mTORC1 and mTORC2 through immunohistochemistry of 18 primary human AT/RT. The PI3K-Akt-mTOR signaling pathway drives tumorigenicity by promoting cancer cell growth and survival. Paxalisib is a highly brain-penetrant PI3K inhibitor acting upstream of mTORC1/2 to fully inhibit the activation of both complexes. Ongoing pediatric clinical trials have reported Paxalisib as safe and well-tolerated, with minimal dose limiting toxicities.} NOTE reiteration of safety profile. Feedback inhibition normally observed with mTORC1 resistance are presented as being overcome by paxalisib, in this John Hopkins study.

IMO, John Hopkins Drug Discovery gave up on their DON drug research and used the safety profile and dual inhibitors (PI3K-Akt-mTOR) of Paxalisib.

Regards.